Insulet (NASDAQ:PODD) Raised to "Strong-Buy" at Zacks Research

Key Points

• Insulet has been upgraded to a "strong-buy" rating by Zacks Research, reflecting increased investor confidence in the company.
• Price targets for Insulet have been raised by multiple financial institutions, with JPMorgan Chase & Co. setting the highest target at $415.00.
• For the most recent quarter, Insulet reported $1.17 EPS, exceeding analysts' expectations and marking a 32.9% year-over-year revenue increase.

Insulet (NASDAQ:PODD - Get Free Report) was upgraded by Zacks Research from a "hold" rating to a "strong-buy" rating in a research note issued to investors on Tuesday,Zacks.com reports.

A number of other equities analysts also recently commented on the company. Barclays boosted their price objective on Insulet from $266.00 to $300.00 and gave the stock an "equal weight" rating in a research report on Thursday, August 21st. Rothschild & Co Redburn upped their price target on Insulet from $350.00 to $370.00 and gave the company a "buy" rating in a report on Friday, October 3rd. Truist Financial began coverage on Insulet in a report on Monday, June 16th. They issued a "buy" rating and a $365.00 price target for the company. JPMorgan Chase & Co. upped their price target on Insulet from $340.00 to $415.00 and gave the company an "overweight" rating in a report on Friday, September 12th. Finally, Wells Fargo & Company upped their price target on Insulet from $330.00 to $350.00 and gave the company an "overweight" rating in a report on Friday, August 8th. One equities research analyst has rated the stock with a Strong Buy rating, eighteen have given a Buy rating and three have assigned a Hold rating to the stock. According to data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $348.05.

Insulet Stock Performance

Shares of Insulet stock opened at $312.45 on Tuesday. Insulet has a one year low of $226.50 and a one year high of $353.50. The company has a market cap of $21.99 billion, a PE ratio of 94.97, a P/E/G ratio of 2.66 and a beta of 1.40. The company has a debt-to-equity ratio of 0.64, a quick ratio of 1.81 and a current ratio of 2.26. The business has a 50-day simple moving average of $325.73 and a 200-day simple moving average of $301.23.

Insulet (NASDAQ:PODD - Get Free Report) last announced its quarterly earnings data on Thursday, August 7th. The medical instruments supplier reported $1.17 EPS for the quarter, topping analysts' consensus estimates of $0.92 by $0.25. Insulet had a return on equity of 23.78% and a net margin of 10.01%.The business had revenue of $649.10 million during the quarter, compared to the consensus estimate of $612.31 million. During the same period in the previous year, the company posted $0.55 earnings per share. The business's revenue for the quarter was up 32.9% on a year-over-year basis. Insulet has set its FY 2025 guidance at EPS. Q3 2025 guidance at EPS. On average, equities research analysts forecast that Insulet will post 3.92 EPS for the current fiscal year.

Insider Buying and Selling

In other Insulet news, SVP Prem Singh sold 687 shares of the business's stock in a transaction that occurred on Monday, September 8th. The stock was sold at an average price of $347.49, for a total value of $238,725.63. Following the completion of the sale, the senior vice president owned 3,456 shares in the company, valued at approximately $1,200,925.44. The trade was a 16.58% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, SVP Laetitia Cousin sold 797 shares of the business's stock in a transaction that occurred on Monday, September 8th. The shares were sold at an average price of $348.81, for a total value of $278,001.57. Following the completion of the sale, the senior vice president owned 3,890 shares of the company's stock, valued at approximately $1,356,870.90. This represents a 17.00% decrease in their position. The disclosure for this sale can be found here. 0.39% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Insulet

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. Farther Finance Advisors LLC raised its stake in shares of Insulet by 85.1% during the first quarter. Farther Finance Advisors LLC now owns 896 shares of the medical instruments supplier's stock worth $236,000 after purchasing an additional 412 shares during the last quarter. GAMMA Investing LLC raised its stake in shares of Insulet by 4.3% during the first quarter. GAMMA Investing LLC now owns 2,529 shares of the medical instruments supplier's stock worth $664,000 after purchasing an additional 105 shares during the last quarter. Wealth Enhancement Advisory Services LLC raised its stake in shares of Insulet by 13.9% during the first quarter. Wealth Enhancement Advisory Services LLC now owns 3,028 shares of the medical instruments supplier's stock worth $795,000 after purchasing an additional 370 shares during the last quarter. Exchange Traded Concepts LLC raised its stake in shares of Insulet by 225.4% during the first quarter. Exchange Traded Concepts LLC now owns 1,552 shares of the medical instruments supplier's stock worth $408,000 after purchasing an additional 1,075 shares during the last quarter. Finally, Janney Montgomery Scott LLC raised its stake in shares of Insulet by 2.9% during the first quarter. Janney Montgomery Scott LLC now owns 5,405 shares of the medical instruments supplier's stock worth $1,419,000 after purchasing an additional 154 shares during the last quarter.

Insulet Company Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.